Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
- Monday, November 15, 2021, 7:13
- PR Newswire
- Add a comment
NEWARK, Calif., Nov. 15, 2021 /PRNewswire/ — Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH)….
About the Author
admin has written 21725 stories on this site.